5TH ANNUAL SUMMIT · BOSTON, USA

AIDDD SUMMIT

Official Agenda 2026

October 27–29 · Boston Marriott Copley Place

1,000+	200+	100+	3
ATTENDEES	SPEAKERS	PARTNERS	DAYS

PROGRAMME TRACKS

- Discovery Biology
- HPC & AI Infrastructure
- Discovery Chemistry
- Clinical Trials
- Data Management & Data Science
- TechOps

Day 1 PLENARY & CROSS-TRACK

Tuesday, October 27, 2026

Opening Keynotes & Innovation Showcase

All tracks · Shared programme

8:00–9:00 AM	*Registration & Welcome Coffee*
9:00 AM–12:30 PM	*Pre-Conference Workshops (Workshops 1–6)*
12:30–1:30 PM	*Lunch & 1-on-1 Meetings*

1:30–1:40 PM

Welcome & Chair's Opening Remarks

Setting the agenda for three days of applied AI insight across the full drug development value chain.

1:40–2:30 PM

EXEC PANEL

C-suite Panel: AI Strategy, Leadership and Transformation in Pharma

Alex Condoleon — Chief Medical Affairs Officer, Pfizer
Wade Davis — SVP Digital, Moderna

Senior pharma leaders share how AI is reshaping R&D investment priorities, organisational structure, and long-term competitive positioning.

2:30–3:00 PM

SPONSOR KEYNOTE

The Agentic AI Shift: Revolutionising R&D and Drug Discovery in Life Sciences

Presented by **Google Cloud**

How autonomous AI agents are moving from pilots to production across the drug discovery value chain—and what it means for R&D organisations today.

3:00–3:30 PM

LUMINARY KEYNOTE

Foundation Models: Opportunities, Challenges, and What's Next

Gabriele Corso — Co-Founder & CEO, Boltz
Joshua Meier — Co-Founder, Chai Discovery

Founders of two leading AI biology companies on where foundation models deliver on their promise, where they fall short, and what the next generation looks like.

3:30–4:00 PM

SPONSOR KEYNOTE

Keynote Presentation — BullFrog AI

Presented by **BullFrog AI**

Applied AI strategies driving measurable outcomes in drug development from one of the sector's emerging innovators.

4:00–4:30 PM	*Afternoon Break & 1-on-1 Meetings*

4:30–5:00 PM

SPONSOR KEYNOTE

Leveraging the AI Cloud for Drug Discovery

Presented by **Vultr**

Cloud infrastructure strategies enabling scalable AI compute for modern drug discovery pipelines—from model training to production inference.

5:00–6:30 PM

INNOVATION SHOWCASE

Innovation Showcase & Reverse Pitches

Nikhil Mutyal — Global Head of Search & Evaluation (Respiratory & Immunology), AstraZeneca
Parthiban Rajasekaran — Global Innovation Lead, Sanofi
Shruti Vij — Director Innovation & AI Strategy, Alexion
Elena Cecilia Diez — Senior Director External Innovation, Johnson & Johnson
Uli Stilz — Board Observer, Aerska

Pharma leaders from five major organisations present their unmet innovation needs—an open signal to the ecosystem on where external AI tools and partnerships are most needed.

6:30–7:30 PM	*Networking Drinks Reception*

Day 2 DISCOVERY BIOLOGY

Wednesday, October 28, 2026

Discovery Biology Track

8:00–9:00 AM *Registration*

9:00–9:30 AM EXEC PANEL

Operationalizing AI in Discovery Biology: From Target Hypothesis to Translational Decision-Making

Morten Sogaard — SVP, Head of Astellas Innovation Lab, Astellas Pharma
Richard Bonneau — VP and Global Head, AI for Drug Discovery, Roche

How leading organizations are shifting to AI-first target identification, embedding multimodal models into discovery workflows, and enabling more confident translational decision-making.

9:30–10:00 AM

Scaling Scientific Capacity: Giving Every Researcher a Team of AI Scientists

Marcos Camara — Director of AI, Sigmatic Sciences
Dave Cooney — Head of GTM Strategy, Sigmatic Sciences

AI tools that augment researcher throughput—enabling smaller teams to deliver the output of a full department without proportional headcount growth.

10:00–10:30 AM

AI for Mechanism-Driven Precision Medicine: Connecting Target Biology to Patient Context

Emanuele de Rinaldis — VP, Global Head of Target, Disease & Systems Biology, Sanofi

How AI clarifies mechanism of action by integrating pathway biology, perturbation data and disease context to strengthen translational confidence before clinical investment.

10:30–11:30 AM *Networking Break & 1-on-1 Meetings*

11:30 AM–12:00 PM

AI-Guided Functional Genomics: From CRISPR Screens to Causal Target Commitment

Wen-Han Yu — Director, Therapeutics & Translational Bioinformatics, Moderna

How AI analysis of CRISPR and Perturb-seq screens distinguishes causal drivers from correlative signals—improving target prioritization before advancing into chemistry.

12:30–1:00 PM

From Sequence to Function: Foundation Models as the New Engine of Target Discovery

How foundation models predict structure, function and interactions directly from sequence data to improve early decisions on target relevance, tractability and risk.

1:00–2:15 PM *Lunch & 1-on-1 Meetings*

2:15–2:45 PM PANEL

Mapping Disease Biology with Single-Cell and Spatial AI

Bart Naughton — Senior Director, Head of Global Discovery Computational Biology, Eisai
Ioannis Vlachos — Associate Professor of Pathology, Harvard Medical School

How AI integrates single-cell and spatial data to map cellular states and tissue architecture in disease—and how cellular heterogeneity informs target localization and safety assumptions.

3:15–3:45 PM

AI-Enabled High-Content Biology: Extracting Mechanism from Imaging and Multi-Omics

How AI-driven phenotypic profiling at scale clarifies mechanism of action and strengthens confidence in early target validation decisions.

3:45–4:30 PM *Afternoon Break & 1-on-1 Meetings*

4:30–5:00 PM

Agentic AI for Experimental Design: Closed-Loop Biology in Target Validation

Dmitriy Podolskiy — AI Drug Discovery Team Lead, Astellas Pharma

How autonomous AI systems propose and refine experimental hypotheses in real time, integrating computational prediction with iterative biological testing to compress validation cycles.

5:30–6:00 PM

Generative AI for Target Hypothesis Design: Moving Beyond Pattern Recognition

Philip Tagari — Chief Scientific Officer, Insitro

How generative AI systems propose mechanistic target hypotheses grounded in multimodal data—going beyond pattern recognition to actively drive target ideation.

6:00–8:00 PM *Drinks Reception & Invite-Only Dinners*

Day 2 DISCOVERY CHEMISTRY

Wednesday, October 28, 2026

Discovery Chemistry Track

8:00–9:00 AM *Registration*

9:00–9:30 AM EXEC PANEL

Scaling AI for Drug Design and Optimization

Peter Clark — VP, Computational Drug Design, Novo Nordisk
Zara Sands — AVP, Eli Lilly

How AI is reshaping molecular design and optimization—and what it takes to scale from promising tools to fully integrated discovery platforms across organizations.

10:00–10:30 AM

AI-Native Molecular Design: Generative Models, Agents and Closed-Loop Chemistry

Richard Bonneau — VP and Global Head, AI for Drug Discovery, Roche

How generative models and agentic systems enable end-to-end AI-integrated medicinal chemistry workflows, from in silico design through iterative lab-in-the-loop optimization.

10:30–11:30 AM *Networking Break & 1-on-1 Meetings*

11:30 AM–12:00 PM

AI-Powered Hit Discovery: Virtual Screening at Ultra-Large Scale

Ian Storer — VP, Hit Discovery & Open Innovation, AstraZeneca

How ML-augmented docking and foundation models improve hit identification accuracy at billion- to trillion-scale virtual libraries, with active learning prioritizing high-value synthesis candidates.

12:30–1:00 PM

Structure-Guided Hit Expansion: From Binding Mode to Lead Series

Jason Cross — Institute Director, Structural and Computational Drug Design, MD Anderson Cancer Centre

How AI refines binding poses and guides hit expansion using hybrid physics-ML approaches to improve confidence in early chemical matter before lead selection.

1:00–2:15 PM *Lunch & 1-on-1 Meetings*

2:15–2:45 PM PANEL

AI-Accelerated Lead Optimization: Physics-Informed Multi-Parameter Molecular Design at Scale

QC Ware

How AI maps high-dimensional SAR to guide molecular refinement, balancing potency, selectivity and developability simultaneously to shorten hit-to-lead timelines.

3:15–3:45 PM

AI for Retrosynthesis and Reaction Prediction

Hubert Misztela — Director Data Science / AI Researcher, Novartis

Data-driven advances in reaction prediction, condition optimization and yield estimation—and how AI agents and human chemists are working together on reaction data.

3:45–4:30 PM *Afternoon Break & 1-on-1 Meetings*

4:30–5:00 PM

Closed-Loop DMTA: Automation in Molecular Optimization

How integrated Design-Make-Test-Analyze platforms with active learning and lab robotics accelerate iterative molecular optimization and reduce experimental burden.

5:30–6:00 PM

Decision-Grade ADME and Property Prediction

Pat Walters — Chief Scientific Officer, OpenADMET

How advanced ML models deliver reliable ADME, PK and developability predictions—and how multi-parameter optimization frameworks de-risk candidate selection and improve clinical success probability.

6:00–8:00 PM *Drinks Reception & Invite-Only Dinners*

Day 2 DATA MANAGEMENT & DATA SCIENCE

Wednesday, October 28, 2026

Data Management & Data Science Track

8:00–9:00 AM *Registration*

9:00–9:30 AM EXEC PANEL

Data Considerations in the AI Era

Haji Aref — Global Head of AI, Data and Integration Architecture, AstraZeneca

Practical strategies for data governance, integration and quality that underpin reliable AI across pharma R&D—and what separates AI-ready organisations from those that are not.

10:00–10:30 AM

Semantics and Improving the FAIR Status of Both Systems and Data

Julia Fox — Director, Data & Analytics, Takeda

Building semantic frameworks to improve the findability, accessibility, interoperability and reusability of pharma data assets—and what it takes to sustain FAIR compliance at scale.

10:30–11:30 AM *Networking Break & 1-on-1 Meetings*

11:30 AM–12:00 PM

Building AI-Ready Data Platforms

Dana Vuzman — Data Science & Translational Research, Wyss Institute

Infrastructure patterns for platforms that serve as reliable, high-quality inputs to modern ML workflows—connecting biological data to production AI pipelines.

12:30–1:00 PM

New Ways to Do Agentic Data Science

Eric Ma — Senior Principal Data Scientist, Moderna

How autonomous agents that query, clean and synthesise data are fundamentally changing how data scientists work—and what new infrastructure is required to support them.

1:00–2:15 PM *Lunch & 1-on-1 Meetings*

2:15–2:45 PM

From Semantics to Scalable AI: Building the Data Foundations for Pharma R&D

Connecting semantic data layers to scalable AI pipelines across the R&D organisation—and what foundations need to be in place before AI can deliver consistent value.

3:15–3:45 PM

Building AI-Ready Data Infrastructure for Scalable Drug Development

Helena Deus — Director Translational Medicine and Semantic Data Products, Bristol Myers Squibb

Engineering data infrastructure to support sustainable, high-quality AI at scale—addressing the storage, access and governance requirements that most organisations underestimate.

3:45–4:30 PM *Afternoon Break & 1-on-1 Meetings*

4:30–5:00 PM

Federated Learning to Build Models in Proprietary Data Without Data Sharing

Rajarshi Guha — Senior Director, Data & Computational Sciences, Vertex

Training on sensitive data without centralising it—enabling cross-organisational collaboration without compromising IP or violating data governance constraints.

5:30–6:00 PM

Metadata Standards and Semantic Consistency

How consistent metadata standards underpin trustworthy, reusable AI models—and the practical steps required to achieve semantic consistency across distributed pharma datasets.

6:00–8:00 PM *Drinks Reception & Invite-Only Dinners*

Day 2 HPC & AI INFRASTRUCTURE

Wednesday, October 28, 2026

HPC & AI Infrastructure Track

8:00–9:00 AM *Registration*

9:00–9:30 AM EXEC PANEL

Building AI-Ready R&D Infrastructure: From Fragmented Pilots to Enterprise Scientific Compute

Faisal Khan — Corporate VP, AI & Analytics, Novo Nordisk
Mark Adams — Partner, TwoBearCapital

How biopharma organizations are moving beyond fragmented AI pilots to build shared, enterprise-grade compute environments—comparing centralized, domain-specific and federated infrastructure models.

9:30–10:00 AM SPONSOR

Lambda Labs: Powering Open Source Model Training to Unlock Drug Discovery Breakthroughs

Chuan Li — Chief Scientific Officer, Lambda Labs

How dedicated GPU infrastructure is powering open-source foundation model training at scale for drug discovery breakthroughs.

10:00–10:30 AM

Hybrid Cloud for Scientific AI: Designing the Right Balance Between On-Prem, Cloud and Colocation

Brian Wong — Director, Advanced Research Computing & Scaled AI/ML, Bristol Myers Squibb

How organizations are balancing workloads across on-prem HPC, elastic cloud and specialized GPU environments—weighing performance, data gravity, sovereignty and procurement risk.

10:30–11:30 AM *Networking Break & 1-on-1 Meetings*

11:30 AM–12:00 PM

Scaling GPU Infrastructure for Drug Discovery: From Model Training to Scientific Compute

Andrew Forman — Global Discovery Solution Architect, Eisai US

How growing demand for model training, inference and simulation is reshaping GPU infrastructure strategies—capacity planning, scheduling and workload prioritization across pharma R&D.

12:30–1:00 PM

From Infrastructure to Enablement: Designing Scientific Platforms for Speed, Scale and Reproducibility

Siddhesh Salunke — Tech Lead, HPC Engineering and Operations, Regeneron

How organizations are redesigning scientific computing platforms around researcher needs—self-service workflows, preconfigured environments and policy-based automation that improve productivity.

1:00–2:15 PM *Lunch & 1-on-1 Meetings*

2:15–2:45 PM

Scientific Foundation Models at Scale: What Infrastructure Changes When Models Become Core R&D Assets?

What changes in storage tiers, interconnects, orchestration and model lifecycle management when biological, chemical and multimodal foundation models become central to R&D strategy.

3:15–3:45 PM

Agentic AI in Production: Infrastructure, Guardrails and Failure Modes for Scientific Workflows

Arvind Rao — Professor of Computation Medicine & Bioinformatics, University of Michigan

How error propagation, tool misuse and cascading failures emerge in multi-agentic systems—and what guardrails are needed to move agentic workflows from promising pilots into routine pharma use.

3:45–4:30 PM *Afternoon Break & 1-on-1 Meetings*

4:30–5:00 PM

AI + Physics at Scale: HPC Infrastructure for Molecular Simulation, Free Energy and Structure-Based Discovery

How modern HPC environments are supporting molecular dynamics, free-energy methods and structure-based workflows—and where physics-based simulation combined with AI improves molecular design confidence.

5:30–6:00 PM

Buying, Building or Partnering: The New Sourcing Model for Scientific Compute

Moderated by **Rahul Mittal** — Head Strategy and Innovation (North America), Dr. Reddy's Laboratories

Decision frameworks for when to own infrastructure, rely on hyperscalers or work with specialist compute partners—and which capabilities should remain strategic in-house as AI becomes central to R&D advantage.

6:00–8:00 PM *Drinks Reception & Invite-Only Dinners*

Day 2 CLINICAL TRIALS

Wednesday, October 28, 2026

Clinical Trials Track

8:00–9:00 AM *Registration*

9:00–9:30 AM EXEC PANEL

From AI Pilots to Scaled Impact in Clinical Trials

Youssef Idelcaid — Head of AI Research Center – Drug Development, Gilead
Subha Madhavan — VP & Head of AI/ML & Digital Sciences, Pfizer
Sandeep Burugapalli — Head of Data Science, AstraZeneca

Senior leaders on what it takes to move AI from fragmented pilots to scaled clinical value—addressing data flows, regulatory pathways and the organizational conditions required for consistent ROI.

10:00–10:30 AM

Validation, Transparency, Audit: What Regulators Now Expect from AI

FDA, MHRA, EMA — *speakers to be confirmed*

How FDA, EMA and MHRA are approaching AI in clinical trials—where guidance is converging or diverging, and what validation, transparency and auditability standards now look like in practice.

10:30–11:30 AM *Networking Break & 1-on-1 Meetings*

11:30 AM–12:00 PM

Where AI Meets Self-Advocacy

Emily Lewis — AI and Innovation Lead, Digital Care Transformation, UCB

A UCB case study on a conversational AI avatar built for the myasthenia gravis community—improving symptom articulation, visit readiness, and trial participation while remaining HIPAA-compliant.

12:30–1:00 PM

AI, Regulation and Sustainability in Drug Development

Maria Florez — Senior Consultant, Tufts

Balancing innovation, regulatory compliance and sustainability across AI-driven drug development pipelines—and where these forces converge or conflict.

1:00–2:15 PM *Lunch & 1-on-1 Meetings*

2:15–2:45 PM

Early-Phase AI Impact

Shaan Gandhi — VP Portfolio Alternative Value Enablement & Head of Partnerships, Pfizer

The measurable value AI is delivering in Phase I and Phase II trial design, execution and commercial performance—with early signals of what scaled impact looks like.

3:15–3:45 PM

From Data to Decision: Building AI-Enabled Infrastructure for Clinical Trial Execution

Ritvik Khandelwal — Data & Analytics Engineer, Praxis Precision Medicines

How near real-time data infrastructure transforms clinical trial execution—improving patient enrollment, site performance and operational efficiency across Phase II/III trials.

3:45–4:30 PM *Afternoon Break & 1-on-1 Meetings*

4:30–5:00 PM

Self-Evolving AI Agents for Clinical Trial Planning

Yi Hong — Associate Director, Clinical Data Science, Gilead

How agent evaluation frameworks and continuous feedback loops enable self-learning and improvement in clinical workflows —and what clinical operations leaders should prioritize now.

5:30–6:00 PM

Scaling Agentic AI Systems Across R&D Use Cases

Jeremy Zhang — Senior Director, Data Science Solutions, Otsuka

What AI infrastructure is genuinely common across R&D use cases—and how to build platforms that serve multiple functions at scale without fragmenting into bespoke point solutions.

6:00–8:00 PM *Drinks Reception & Invite-Only Dinners*

Day 2 TECHOPS

Wednesday, October 28, 2026

TechOps Track

8:00–9:00 AM *Registration*

9:00–9:30 AM EXEC PANEL

Unlocking Data for Improved Manufacturing Outcomes

Identifying the data assets, integration strategies and governance models that unlock AI value in pharma manufacturing—and where organisations are still leaving value on the table.

10:00–10:30 AM

From Data to Decisions: Enabling AI-Driven Manufacturing Through Process Monitoring Data Maturity

Jack Prior — Head of Process Monitoring and Data Science/AI Strategy, Sanofi

Translating process monitoring data into actionable AI insights for real-time manufacturing decisions—and the data maturity journey required to get there.

10:30–11:30 AM *Networking Break & 1-on-1 Meetings*

11:30 AM–12:00 PM

Cross-Functional Lessons to Improve AI Deployment in Process Development and Manufacturing

Ray Forslund — Product Development, Syner-G
Jen Kilroy — SVP Strategy & Transformation, Syner-G
Shruti Vij — Director Innovation and AI Strategy, Alexion

What works—and what doesn't—when deploying AI across manufacturing and process development, drawing on cross-functional lessons from both pharma and service providers.

12:30–1:00 PM

AI Roadmap for Process Development

Yasser Jangjou — Head of Drug Substance Process Engineering, Sanofi

Building a coherent AI strategy for process chemistry and development organisations—sequencing investments, managing change, and demonstrating value at each stage of the roadmap.

1:00–2:15 PM *Lunch & 1-on-1 Meetings*

2:15–2:45 PM

Applying AI, PAT and Real-Time Analytics in Process Development and Manufacturing

Preeya Bopanna — Director MS&T Process Analytics and Laboratories, AstraZeneca

Integrating process analytical technology with AI for real-time manufacturing optimization—and where PAT data creates the richest opportunity for AI-driven process control.

3:15–3:45 PM

Scalability and Quality Impact in AI in Process Development

Dana Filoti — Associate Director, EBE PDS&T Analytical Development & Digital Strategy, AbbVie

Maintaining quality outcomes as AI-driven process development scales—and what governance structures are needed to prevent quality drift as AI systems take on more autonomous decisions.

3:45–4:30 PM *Afternoon Break & 1-on-1 Meetings*

4:30–5:00 PM

Sandboxes, Stewards and the Governance Gap

Martin Kockx — Principal Manufacturing Systems Engineer, Vertex

Practical governance models for managing AI tools safely in regulated manufacturing environments—addressing the gap between innovation velocity and compliance requirements.

5:30–6:00 PM

ML Applications in Pharma Process Development

Rose Yin — Senior Scientist, Merck
Sponsored by **Syner-G**

Machine learning use cases delivering measurable value in active pharmaceutical ingredient development—what is working, at what scale, and what obstacles remain.

6:00–8:00 PM *Drinks Reception & Invite-Only Dinners*

Day 3 DISCOVERY BIOLOGY

Thursday, October 29, 2026

Discovery Biology Track

8:00–9:00 AM *Registration*

9:00–9:30 AM EXEC PANEL

Assessing AI ROI in Clinically Anchored Target Identification and Validation

Walid Kamoun — Vice President, Global Head of R&D Oncology, Servier

Where AI has genuinely strengthened clinically relevant target hypotheses—and where it has failed to translate into better discovery decisions. What determines whether AI capability becomes differentiated R&D advantage.

9:30–10:00 AM

Thinking in 10,000 Dimensions: Hyperdimensional Computing as the Bio-Native Layer of Drug Discovery

Dirk Van Hyfte — MD PhD, Chief Technology Officer, MindWalk Holdings Corp.

An alternative computing paradigm that mirrors biological data structures—how hyperdimensional computing enables more native modelling of molecular and cellular complexity.

10:00–10:30 AM

From DeepFold to Deep Function: AI for Protein Interactions, Structure and Druggability Assessment

How structural AI advances understanding of protein interactions, conformational states and functional modulation—moving from structure prediction to druggability assessment and modality decisions.

10:30–11:30 AM *Networking Break & 1-on-1 Meetings*

11:30 AM–12:00 PM

Multimodal Biomarker Discovery: AI for Early Disease Detection and Patient Stratification

Vinayagam Arunachalam — Senior Director, Head of Computational Biology and Digital Early Development & Biomarkers, Takeda

Maen Obeidat — Executive Director, Therapeutic Area Head, Biomarker Development, Translational Medicine, Novartis

How AI integrates genomic, proteomic and clinical signals to uncover target-linked biomarkers—supporting earlier, more precise stratification hypotheses and better alignment between discovery and clinical strategy.

12:30–1:00 PM

Uncovering Disease Heterogeneity with AI and Real-World Data

Sabah Kadri — Senior Director, Head of Quantitative Insights Lab, AbbVie

How AI integrates multi-modal data to reveal actionable insights across heterogeneous patient populations—and how disease subtype and treatment-response variability can directly inform drug discovery.

1:00–2:00 PM *Lunch (Women in AI Lunch · Discovery Biology)*

2:00–2:30 PM

AI-Enabled Biologics Design

Shipra Malhotra — Associate Director, AI/ML Biologics, Takeda

Structure-informed and structure-free AI approaches to biologics design—how AI compresses design-make-test cycles while improving developability, affinity and real-world value.

2:30–3:00 PM PANEL

AI-Guided Protein Engineering: From Sequence Design to Experimental Validation

How closed-loop design-build-test-learn workflows reduce experimental cycles in AI-generated protein candidates while increasing confidence in biological relevance and developability.

3:00–3:30 PM

Beyond the Hypothesis: How Systematic Data Exploration is Delivering Validated Oncology Targets

Francisca Vazquez — Senior Group Leader, Target Discovery and Advancement Lab, MIT Broad Institute

How large-scale functional and omics datasets, interrogated through systematic unbiased approaches, can reveal high-confidence oncology targets—with real-world examples now in preclinical and clinical development.

3:30–4:30 PM *Roundtable Discussions*

Day 3 DISCOVERY CHEMISTRY

Thursday, October 29, 2026

Discovery Chemistry Track

8:00–9:00 AM *Registration*

9:00–9:30 AM EXEC PANEL

Measuring Real Impact: Is AI Improving Chemistry Success Rates?

Stewart New — Head of Computational Drug Discovery, Incyte

How organizations are evaluating the real-world impact of AI on drug discovery productivity—examining which metrics matter across hit discovery, optimization and candidate selection.

9:30–10:00 AM

The AI Integration Layer: How MCPs and APIs Are Reshaping the Drug Discovery Workflow

Edward Vineall — Account Director, Patsnap

How standardized interfaces are enabling plug-and-play AI tools across the chemistry stack—and what the emerging AI integration layer means for how drug discovery workflows are designed.

10:00–10:30 AM

AI for Targeted Protein Degradation: PROTAC and Molecular Glue Design

Scott Johnson — Scientific Associate Director, Computer-Aided Drug Design, Bristol Myers Squibb

How AI supports bifunctional molecule design for targeted protein degradation—predicting ternary complex formation, optimizing linkers and accelerating the discovery of next-generation degraders and molecular glues.

10:30–11:30 AM *Networking Break & 1-on-1 Meetings*

11:30 AM–12:00 PM

Early Safety Prediction: Off-Target and Toxicity Modeling

How AI models help identify potential safety risks earlier in drug discovery—examining compound liabilities alongside potency and developability to reduce late-stage attrition.

12:00–12:30 PM

On-Chip Drug Discovery for the AI Era – Beyond 50+ Years of Microwell Plates

Bharath Takulapalli — Founder & CEO, SPOC Biosciences

Next-generation microfluidics platform enabling drug discovery experiments beyond traditional well-plate formats—how on-chip approaches expand what is measurable at speed and scale.

12:30–1:00 PM

AI for Biologic and Large Molecule Engineering

Saber Meamardoost — Associate Director AI/ML and Data Science, Boehringer Ingelheim

How predictive and generative models enable antibody, peptide and protein sequence design—improving affinity, stability, specificity and immunogenicity profiles while expanding the accessible design space.

1:00–2:00 PM *Lunch & 1-on-1 Meetings*

2:00–2:30 PM

AI-Enabled Drug Repurposing and Indication Expansion

Nikhil Pillai — Senior Principal Scientist, Quantitative Pharmacology – Pharmacometrics, Sanofi

How multimodal data integration and network-based approaches reveal novel disease-target-compound relationships—and how AI-driven repurposing reduces development risk and compresses time to market.

3:00–3:30 PM

Chemical Foundation Models and LLMs: From Molecular Generation to Reaction Intelligence

How foundation models trained on chemical data enable de novo molecular design, retrosynthesis and reaction prediction—and where LLMs are improving synthesis planning and design quality.

3:30–4:30 PM *Roundtable Discussions*

Day 3 DATA MANAGEMENT & DATA SCIENCE

Thursday, October 29, 2026

Data Management & Data Science Track

8:00–9:00 AM *Registration*

9:00–9:30 AM EXEC PANEL

From Bio-Data Foundations to AI-Ready Target Discovery

Michael Steinbaugh — Director, Data, AI, and Genome Sciences, Merck

Linking robust biological data infrastructure to actionable AI outputs in target discovery—and what data foundation investments deliver the greatest impact on discovery productivity.

10:00–10:30 AM

Democratizing ML in Pharma R&D: Building Infrastructure for Model Access, Versioning, and Interoperability

Mark Aquino — Principal Data Scientist II, AbbVie

Infrastructure that makes ML accessible to all R&D functions—not just dedicated data science teams—through model access, versioning and interoperability at scale.

10:30–11:30 AM *Networking Break & 1-on-1 Meetings*

11:30 AM–12:00 PM

Building the Data Aggregation Continuum: Connecting Medical, Clinical, and Commercial Insights Across Pharma

Bhaskar Dutta — Head of Digital Health, Alexion

Connecting medical, clinical and commercial data streams into a unified AI-ready insight layer—and what architecture choices enable cross-study learning at enterprise scale.

12:30–1:00 PM

Privacy, Consent and Data Control

Navigating data privacy frameworks and patient consent requirements in AI-enabled drug development—and what organisations need to maintain trust while enabling data utility.

1:00–2:00 PM *Lunch & 1-on-1 Meetings*

2:00–2:30 PM

Data Standardization for Reuse and Collaboration

Standards and ontologies that enable data to be shared, reused and interpreted consistently—and the practical steps required to sustain semantic consistency across distributed pharma datasets.

3:00–3:30 PM

Legacy Systems and Modern Data Management

Strategies for integrating and transforming legacy data assets for modern AI pipelines—addressing the technical debt, migration risk and organisational friction that slow AI adoption.

3:30–4:30 PM *Roundtable Discussions*

Day 3 HPC & AI INFRASTRUCTURE

Thursday, October 29, 2026

HPC & AI Infrastructure Track

8:00–9:00 AM *Registration*

9:00–9:30 AM EXEC PANEL

What Comes After Discovery? Extending Scientific Compute Strategy Across Development and Operations

How pharma organizations are broadening compute strategy from research into development and technical operations—what stays the same and what changes as AI is expected to deliver impact beyond early discovery.

9:30–10:00 AM SPONSOR

Sponsor Presentation — Bluenote

Presented by **Bluenote**

How Bluenote is addressing a key HPC or AI infrastructure challenge in pharma R&D.

10:00–10:30 AM

Real-Time Scientific Compute in the Lab: Building Infrastructure for Closed-Loop R&D

Yves Fomekong Nanfack — Head of AI/ML Research, Takeda

How lab infrastructure evolves to support real-time data capture, model-driven experimentation and faster decision-making—moving from isolated automation projects to scalable closed-loop R&D workflows.

10:30–11:30 AM *Networking Break & 1-on-1 Meetings*

11:30 AM–12:00 PM

Data Infrastructure for Scientific AI: Moving, Storing and Serving Data at Scale

Haji Aref — Global Head of AI, Data and Integration Architecture, AstraZeneca

How data engineering challenges change as AI, simulation and multimodal workflows demand more from scientific infrastructure—storage tiers, data locality, throughput and reproducible access at scale.

12:30–1:00 PM

Secure AI Inference at Scale: Building Trusted Infrastructure for Pharma R&D

Philippe Assouline — Senior Director, Group Head of Technology & Enterprise Architecture, Teva Pharmaceuticals

What infrastructure and engineering teams need in place as models and scientific agents move into production—secure inference architectures, access control, model integrity and auditability.

1:00–2:00 PM *Lunch & 1-on-1 Meetings*

2:00–2:30 PM

Scaling AI in Regulated Environments: Infrastructure, Governance and Deployment Realities

What it takes to deploy AI where validation, traceability, access control and oversight matter—and how to balance innovation velocity with compliance as AI adoption expands across development.

3:00–3:30 PM

Infrastructure Operating Models for AI-Enabled R&D: Who Owns the Platform, the Compute and the Risk?

Ben Ellingson — Director II, Scientific Informatics and Computation, AbbVie

How pharma organizations are structuring ownership of AI infrastructure across R&D IT, data science, platform teams and research functions—comparing centralized, federated and hybrid operating models.

3:30–4:30 PM *Roundtable Discussions*

Day 3 CLINICAL TRIALS

Thursday, October 29, 2026

Clinical Trials Track

8:00–9:00 AM *Registration*

9:00–9:30 AM EXEC PANEL

Building the AI-Ready Data Layer

James O'Keefe — Head of Regulatory Information, Data and Systems, Takeda

What it takes to unify EDC, CTMS, imaging, biomarker and operational data into a cohesive, AI-ready layer—and which architectural and interoperability standards are emerging to support scalable analytics.

10:00–10:30 AM

Embedding AI into Regulated Workflows: Validation, Governance & Lifecycle

Digital Medicine Society

What validation frameworks for AI-enabled tools look like in practice—how organisations are managing adaptive model performance, monitoring, controlled updates and cross-functional governance in GxP environments.

10:30–11:30 AM *Networking Break & 1-on-1 Meetings*

11:30 AM–12:00 PM

Build, Buy or Both? Navigating the AI Vendor Maze

When to consolidate onto unified platforms vs. integrate best-of-breed solutions—where organisations are encountering vendor lock-in risk and how governance and architecture choices determine scalability.

12:30–1:00 PM

Post-Approval Reality: Keeping AI Compliant, Current and Inspection-Ready

What post-approval AI lifecycle management looks like in practice—drift detection, re-validation triggers, inspection-ready documentation and how to operationalize ongoing oversight without slowing innovation.

1:00–2:00 PM *Lunch & 1-on-1 Meetings*

2:00–2:30 PM

Cardinal Trials: An Open-Source Data-Driven Clinical Benchmarking Platform

Peter Henstock — Machine Learning Group Leader, Incyte

A new open-source platform for benchmarking AI performance against clinical trial data—enabling standardized evaluation and comparison of AI tools in clinical development settings.

3:00–3:30 PM

AI Credibility Assessment Framework for Regulated Environments

Jagdeep Podichetty — Senior Director GenAI/ML, Critical Path Institute

A structured framework for validating AI model robustness, reproducibility and transparency in regulated drug development —how data provenance, bias assessment and performance benchmarking fit into model credibility.

3:30–4:30 PM *Roundtable Discussions*

Day 3 TECHOPS

Thursday, October 29, 2026

TechOps Track

8:00–9:00 AM *Registration*

9:00–9:30 AM EXEC PANEL

Decision Enhancement to Improve Time to Market

AI decision-support tools targeting the manufacturing bottlenecks that slow time to first patient—where decision enhancement is delivering measurable reductions in cycle time and human review burden.

10:00–10:30 AM

ML Applications in Pharma Process Development

Rose Yin — Senior Scientist, Merck

Machine learning use cases in process development—what is working, at what scale, and the obstacles that remain for teams trying to move from proof-of-concept to operational deployment.

10:30–11:30 AM *Networking Break & 1-on-1 Meetings*

11:30 AM–12:00 PM

Biopharmaceutical Characterization in the Age of Artificial Intelligence

Jared Auclair — Dean, Northeastern University College of Professional Studies; Director, Bioinnovation, Northeastern University

How AI is accelerating analytical method development and biopharmaceutical characterization—and what it means for the speed and confidence of regulatory submissions.

12:30–1:00 PM

Improving Supply Reliability and Planning Through Better Forecasting and Process Insight

AI-driven supply chain forecasting and process monitoring for improved manufacturing reliability—connecting process insight to supply planning decisions that currently rely on manual judgment.

1:00–2:00 PM *Lunch & 1-on-1 Meetings*

2:00–2:30 PM

Maximizing Value of Digital Infrastructure to Support Process Optimization at Scale

Connecting digital infrastructure investment to measurable improvements in process development outcomes—how to extract maximum value from existing systems before investing in new ones.

3:00–3:30 PM

Judging ROI from AI in Manufacturing Challenges

Frameworks for evaluating the real business value of AI investments in pharma manufacturing—how to define success, measure outcomes, and build the internal case for continued investment.

3:30–4:30 PM *Roundtable Discussions*